Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: Ziltivekimab in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
NCT06200207Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of ziltivekimab in heart failure (HF), sponsored by Novo Nordisk. Started Apr 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06200207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200207.